{"id":42096,"date":"2024-07-01T11:58:20","date_gmt":"2024-07-01T09:58:20","guid":{"rendered":"https:\/\/www.satt.fr\/?p=42096"},"modified":"2024-07-02T10:26:08","modified_gmt":"2024-07-02T08:26:08","slug":"occentis","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/occentis\/","title":{"rendered":"La Success story du mois : OCCENTIS"},"content":{"rendered":"
\n
\n\t

#Occentis r\u00e9volutionne le traitement de l\u2019autisme\u00a0 !<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\"\"<\/div><\/div>
\n
\n\t

Occentis d\u00e9veloppe une nouvelle th\u00e9rapie prometteuse pour le traitement de l\u2019autisme, des douleurs neuropathiques et de la d\u00e9pendance \u00e0 l\u2019alcool.<\/strong><\/p>\n

La SATT Conectus a sign\u00e9 une licence exclusive avec Occentis SAS, une toute nouvelle startup soutenue par Neurentis plc et d\u00e9di\u00e9e au d\u00e9veloppement d\u2019un nouveau candidat-m\u00e9dicament issu de travaux de recherche du Laboratoire d\u2019Innovation Th\u00e9rapeutique (UMR 7200 CNRS - Universit\u00e9 de Strasbourg). Les r\u00e9sultats pr\u00e9cliniques confirment un potentiel th\u00e9rapeutique majeur pour la prise en charge des troubles autistiques, des douleurs neuropathiques et le sevrage alcoolique.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

C\u2019est au terme de 20 ann\u00e9es de recherches intenses qu\u2019a \u00e9merg\u00e9 une nouvelle mol\u00e9cule r\u00e9volutionnaire mimant l\u2019ocytocine tout en pr\u00e9sentant une efficacit\u00e9 et une s\u00e9lectivit\u00e9 sup\u00e9rieure<\/strong> \u00e0 cette hormone-cl\u00e9 impliqu\u00e9e dans plusieurs m\u00e9canismes physiologiques et comportementaux, tels que les relations sociales, la gestion de la douleur ou encore les addictions.<\/p>\n

Cette d\u00e9couverte scientifique revient \u00e0 Marcel HIBERT, professeur \u00e9m\u00e9rite de chimie organique \u00e0 la Facult\u00e9 de Pharmacie de l\u2019Universit\u00e9 de Strasbourg, expert international de l\u2019ocytocine, et ancien Directeur du LIT Laboratoire d\u2019Innovation Th\u00e9rapeutique<\/strong> (UMR 7200 CNRS-Universit\u00e9 de Strasbourg) :<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
<\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\u00a9 Laurence Honnorat<\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t

\" Il n\u2019existait jusqu\u2019alors aucune approche th\u00e9rapeutique qui cible le d\u00e9ficit d\u2019interaction sociale des patients autistes. Depuis le d\u00e9but des ann\u00e9es 2000, les biologistes ont montr\u00e9 que l\u2019ocytocine produite par notre cerveau \u00e9tait n\u00e9cessaire \u00e0 la compr\u00e9hension des codes de communication et de construction sociale. Malheureusement cette hormone ne pouvait pas \u00eatre utilis\u00e9e directement comme m\u00e9dicament. Les travaux de notre \u00e9quipe ont permis de concevoir et d\u00e9velopper une mol\u00e9cule mimant l\u2019ocytocine mais avec les caract\u00e9ristiques requises pour un d\u00e9veloppement th\u00e9rapeutique. \"<\/em><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

Cette nouvelle approche th\u00e9rapeutique pourrait apporter des solutions \u00e0 trois grands enjeux de sant\u00e9 publique : l\u2019autisme, l\u2019alcoolisme et les douleurs neuropathiques<\/strong>. Les troubles du spectre autistique touchent aujourd\u2019hui au moins 1 personne sur 100 dans le monde1<\/sup>.<\/p>\n

Toujours sur le plan mondial, ce sont 283 millions de personnes qui, sur les 8 principaux march\u00e9s (USA, All., Royaume-Uni, France, Italie, Espagne, Japon, Chine)2<\/sup> souffrent de troubles li\u00e9s \u00e0 l\u2019alcool et sont en attente de traitements plus efficaces. Enfin, les douleurs neuropathiques li\u00e9es au diab\u00e8te affectent 7,8 millions de personnes sur les principaux march\u00e9s pr\u00e9cit\u00e9s.3<\/sup><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

Quand innovation scientifique rime avec startup<\/strong><\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div>
\n
\n\t

Ce projet innovant a pu se concr\u00e9tiser gr\u00e2ce \u00e0 un investissement majeur de la SATT Conectus<\/strong> \u00e0 une \u00e9tape-cl\u00e9 o\u00f9 peu d\u2019investisseurs se risquent.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
<\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\u00a9 St\u00e9phane Mery<\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t

St\u00e9phane MERY, Pr\u00e9sident d\u2019Occentis SAS<\/strong>, confirme l\u2019ambition : \u00ab L\u2019ambition d\u2019Occentis est de cr\u00e9er un acteur majeur dans le domaine de la Psychiatrie. Notre strat\u00e9gie de croissance repose sur la licence de projets innovants. Le programme de d\u00e9veloppement d\u2019analogues de l\u2019ocytocine port\u00e9 par le Professeur Hibert et Conectus est de loin le projet le plus prometteur de tous ceux que nous avons investigu\u00e9s au niveau mondial. Il repr\u00e9sente un m\u00e9canisme d\u2019action v\u00e9ritablement nouveau dans le traitement de plusieurs maladies o\u00f9 les innovations sont rares et plus souvent de l\u2019ordre du \u2018me too\u2019. Occentis est aussi tr\u00e8s fi\u00e8re d\u2019\u00eatre soutenue par Neurentis \u00bb.<\/em><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

Occentis SAS est actuellement incub\u00e9e chez SEMIA \u00e0 Strasbourg.<\/strong> La startup s\u2019est \u00e9tablie en Alsace pour continuer \u00e0 profiter de l\u2019excellence scientifique des \u00e9quipes inventrices mais aussi de toute la dynamique partenariale de l\u2019\u00e9cosyst\u00e8me alsacien, particuli\u00e8rement performante sur tous les enjeux d\u2019innovations-sant\u00e9.<\/p>\n

Les priorit\u00e9s \u00e0 venir devraient porter sur la d\u00e9finition de la pathologie prioritaire retenue pour d\u00e9montrer la future efficacit\u00e9 clinique<\/strong> ainsi que le lancement des d\u00e9marches r\u00e9glementaires<\/strong> n\u00e9cessaires \u00e0 la prochaine \u00e9tape d\u2019\u00e9tudes cliniques. Une lev\u00e9e de fonds est par ailleurs envisag\u00e9e d\u00e8s 2024<\/strong> pour financer ces prochaines \u00e9tapes cruciales.<\/p>\n

 <\/p>\n

1<\/sup> source : Autism (who.int)<\/em>
\n2<\/sup> Alcohol Use Disorder Treatment Market Size, Share And Growth Analysis, 2030 (researchnester.com)<\/em>
\n3<\/sup> GlobalData (2023) Painful Diabetic Neuropathy: Epidemiology Forecast to 2031, January 2023<\/em><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

D\u00e9couvrir Occentis<\/span><\/span><\/strong><\/a><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

#Occentis r\u00e9volutionne le traitement de l\u2019autisme\u00a0 ! Occentis d\u00e9veloppe une nouvelle th\u00e9rapie prometteuse pour le traitement de l\u2019autisme, des douleurs neuropathiques et de la d\u00e9pendance \u00e0 l\u2019alcool. La SATT Conectus a sign\u00e9 une licence exclusive avec Occentis SAS, une toute nouvelle startup soutenue par Neurentis plc et d\u00e9di\u00e9e au d\u00e9veloppement d\u2019un nouveau candidat-m\u00e9dicament issu de […]<\/p>\n","protected":false},"author":2,"featured_media":42114,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567],"tags":[],"class_list":["post-42096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"yoast_head":"\nLa Success story du mois : OCCENTIS - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/occentis\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"headline\":\"La Success story du mois : OCCENTIS\",\"datePublished\":\"2024-07-01T09:58:20+00:00\",\"dateModified\":\"2024-07-02T08:26:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/\"},\"wordCount\":500,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/\",\"url\":\"https:\/\/www.satt.fr\/en\/occentis\/\",\"name\":\"La Success story du mois : OCCENTIS - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg\",\"datePublished\":\"2024-07-01T09:58:20+00:00\",\"dateModified\":\"2024-07-02T08:26:08+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/occentis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg\",\"width\":1614,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/occentis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Success story du mois : OCCENTIS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\",\"name\":\"admin\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Success story du mois : OCCENTIS - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/occentis\/","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/occentis\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/occentis\/"},"author":{"name":"admin","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"headline":"La Success story du mois : OCCENTIS","datePublished":"2024-07-01T09:58:20+00:00","dateModified":"2024-07-02T08:26:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/occentis\/"},"wordCount":500,"image":{"@id":"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/occentis\/","url":"https:\/\/www.satt.fr\/en\/occentis\/","name":"La Success story du mois : OCCENTIS - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg","datePublished":"2024-07-01T09:58:20+00:00","dateModified":"2024-07-02T08:26:08+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/occentis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/occentis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/occentis\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/07\/Occentis.jpg","width":1614,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/occentis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"La Success story du mois : OCCENTIS"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec","name":"admin","url":"https:\/\/www.satt.fr\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/42096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=42096"}],"version-history":[{"count":5,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/42096\/revisions"}],"predecessor-version":[{"id":42167,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/42096\/revisions\/42167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/42114"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=42096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=42096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=42096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}